VIRAMUNE XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIRAMUNE XR is an extended-release oral tablet containing nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV treatment. The mechanism of action involves inhibition of HIV reverse transcriptase to reduce viral replication. This product represents a formulation advancement over immediate-release nevirapine, enabling once-daily dosing for improved patient adherence.
LOE Approaching2.5 years to LOE
With LOE approaching in 2.5 years, this product team is in transition planning mode; expect smaller commercial footprint compared to growth-stage franchises.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on VIRAMUNE XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.